Rubius Therapeutics Reports Second Quarter 2018 Financial

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
80
Rubius Therapeutics Reports Second Quarter 2018 Financial Results

CAMBRIDGE, Mass., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biotechnology company pioneering the development of a new class of ready-to-use cellular therapies, today reported second quarter 2018 financial results.

As of June 30, 2018, Rubius had cash, cash equivalents and marketable securities of $181.7 million. This amount excludes $257.9 million of proceeds after deducting underwriting discounts and commissions from Rubius’ initial public offering (IPO), which closed in July 2018. Based upon its current operating plan, Rubius expects its existing capital resources will be sufficient to fund operations into 2021.

“We have made significant progress over the course of this year - the highlight of which was the closing of our IPO,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius Therapeutics, Inc. “The IPO proceeds give Rubius the resources to execute against our vision of creating life-changing cellular medicines to treat patients with rare diseases, cancer and autoimmune diseases. We are on track to file our first Investigational New Drug application for RTX-134 during the first quarter of 2019, for the treatment of patients with phenylketonuria, a rare disease affecting approximately 16,500 people in the U.S.” 1

Recent Business Highlights

Initial Public Offering

  • On July 23, 2018, Rubius closed its IPO, raising $257.9 million of proceeds after deducting underwriting discounts and commissions. The proceeds from this offering, together with existing cash, cash equivalents and marketable securities are expected to be used:
    • to purchase, renovate, customize and operate its manufacturing facility;
    • to advance RTX-134 through a Phase 1/2a clinical proof-of-concept trial;
    • to advance and expand its RED PLATFORM ™  and its research and development pipeline, including early discovery efforts and IND-enabling studies, and to initiate additional proof-of-concept trials in rare diseases, cancer and autoimmune diseases; and for working capital and other general corporate purposes. 

Manufacturing Facility

  • On July 31, 2018, Rubius purchased an existing 135,000-square foot manufacturing facility in Smithfield, Rhode Island.
  • The company plans to invest approximately $95.0 million through 2020, which includes the $8.0 million purchase price.

Strategic Hires and Internal Capabilities

  • Continued to build a leading scientific team and attract experienced leadership to deliver against Rubius’ vision, including the hiring of Pablo J. Cagnoni, M.D., as chief executive officer.
  • Strengthened internal capabilities in discovery, platform and therapeutic development and manufacturing.

Second Quarter Financial Results Cash, cash equivalents and marketable securities totaled $181.7 million as of June 30, 2018, compared to $104.3 million as of December 31, 2017. The increase in cash reflects the net proceeds from Rubius’ Series C preferred stock financing during the first quarter of 2018, offset by its cash used in operations during the period. Research and development expenses were $12.0 million during the second quarter of 2018, compared with $4.8 million for the second quarter of 2017. The increase was attributable to costs incurred in preparation of Rubius’ planned Phase 1/2a clinical trial of RTX-134 in phenylketonuria, as well as an increase in headcount in its research and development function and an increase in external manufacturing and research costs to improve and expand its manufacturing capabilities, prepare for clinical scale production and expand its in vivo testing to support clinical candidate selection. General and administrative expenses were $16.3 million during the second quarter of 2018, compared to $4.2 million for the second quarter of 2017. The increase was primarily due to an increase in stock-based compensation and increases in personnel costs and professional fees as Rubius prepared to operate as a public company.

About Rubius Therapeutics Rubius Therapeutics is a biopharmaceutical company pioneering the development of a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit  www.rubiustx.com  or follow us on  Twitter .

Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the anticipated use of our existing cash resources, including proceeds from our IPO, the during for which our existing capital resources will fund our operations, the renovation and operation of the manufacturing facility for which we have entered into a purchase and sale agreement, the therapeutic potential of our Red Cell Therapeutics, the timeline for us to file an IND, and our strategy, business plans and focus. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the development of our Red Cell Therapeutic product candidates and their therapeutic potential and other risks identified in our SEC filings, including our Prospectus filed with the SEC on July 18, 2018, as amended, and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

______________________________

1 https://npkua.org/Education/About-PKU

Rubius Therapeutics, Inc. Condensed Consolidated Statement of Operations (in thousands, except per share data) (unaudited)

  For the three months ended June 30,   For the six months ended June 30,
  2018     2017     2018     2017  
Revenue $       $       $       $    
Operating expenses:                              
Research and development   11,965       4,821       21,615       8,502  
General and administrative   16,279       4,212       22,076       5,314  
Total operating expenses   28,244       9,033       43,691       13,816  
Loss from operations   (28,244 )     (9,033 )     (43,691 )     (13,816 )
Other expense, net   (855 )      (521 )     (663 )     (595 )
Net loss $ (29,099 )   $ (9,554 )   $ (44,354 )   $ (14,411 )
Accretion of Series A redeemable convertible preferred stock to redemption value           (280 )             (656 )
Net loss attributable to common stockholders $ (29,099 )   $ (9,554 )   $ (44,354 )   $ (14,411 )
Net loss per share - basic and diluted: $ (3.33 )   $ (1.25 )   $ (5.19 )   $ (1.93 )
Weighted-average number of common shares used in computing net loss per share - basic and diluted:   8,727,392       7,866,955       8,542,362       7,808,681  

Rubius Therapeutics, Inc. Condensed Consolidated Balance Sheet Data (in thousands) (unaudited)

  June 30,   December 31,
  2018   2017
Cash, cash equivalents and marketable securities $ 181,730   $ 104,288
Total assets   207,533     107,687
Total liabilities   37,466     11,584
Total stockholders' deficit and convertible preferred stock   170,067     96,103

Media Contact:  Dan Budwick 1AB, Inc. +1 (973) 271-6085 dan@1abmedia.com

Investor Contact: Lori Melançon Vice President, Corporate Communications and Investor Relations +1 (617) 229-6122 lori.melancon@rubiustx.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Carbonization Furnaces Turn Waste Rules Into Demand

Updated Category News Views 84

Smoke has become an expensive habit for farmers, mills, and municipalities. That is the real commercial backdrop for carbonization furnaces, not some glossy green-tech slogan. MarketsandMarkets estimates this small global equipment market at $310 million in 2026 and projects $510 million by 2031, a 10.2% compound annual growth rate. For a capital-equipment niche, that is...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 77

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading
Colon Cleanse Advice Deserves a Careful Read First

Updated Category News Views 59

Wellness copy can sound harmless right up until it blurs comfort guidance with health guidance. HelloNation’s feature on what to expect after a colon cleanse, drawing on Suzanne Childre of Gentle Wellness Center in Santa Monica, lays out a fairly familiar recovery script: drink water, rest, eat lightly, expect some bowel changes, and do not panic over a little fatigue....

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 56

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 60

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 146

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
AWK Adds Fayette Water System With $9M Upgrade Plan

Updated Category News Views 140

Small water systems do not usually collapse in one dramatic heap; they get worn down by scattered pipes, compliance demands, thin staffing and bills nobody wants to raise. That is the backdrop for Pennsylvania American Water’s completed $32.8 million purchase of the Indian Creek Valley Water Authority system. For American Water shareholders, this is the familiar...

Continue Reading
RAN Rebound Gains Speed, but 2027 Still Looks Flat

Updated Category News Views 101

Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...

Continue Reading
Implantica's U.S. Launch Arrives With Cash Still to Burn

Updated Category News Views 104

RefluxStop has finally stepped onto American soil, and that changes the conversation around Implantica in a very real way. FDA Premarket Approval arrived on August 20, then the first U.S. procedures were completed in early November at the University of Southern California. For a small medtech outfit, clearing that regulatory gate and getting actual patients treated are...

Continue Reading
Elanco’s $600 Million Buyback Signals a New Chapter

Updated Category News Views 84

Debt coming down and cash coming in finally gave Elanco room to breathe. On Nov. 19, 2026, the animal-health company authorized its first-ever share repurchase program, allowing up to $600 million of common-stock purchases. For NYSE: ELAN, this is more than a flashy capital-return headline. It marks a shift from the ugly but necessary job of balance-sheet repair toward a...

Continue Reading

Top 5 Most Recently Viewed Articles

Degree Deodorant Shakes Up NYC Subway with Savvy Ads

Updated Category News Views 28

Sweat and Laughter in the Big Apple Here we go again, folks! Degree Deodorant, the top dog in the antiperspirant world, is spicing up New York City's subway stations this summer. Now, I know what you're thinking: subway rides and deodorant—what a combo! But trust me, their new advertising campaign is a stroke of genius. It's inspired by those memorable, sweaty summer...

Continue Reading
Cupid's Senior Squad Ready to Share Dating Wisdom

Updated Category News Views 91

Cupid's Senior Squad Ready to Share Dating Wisdom As Valentine's Day approaches, many look for meaningful advice on relationships and dating. Instead of relying on dating apps or self-proclaimed experts, you can trust the Cupid Senior Squad to provide wisdom gained over decades of love. Located at RiverSpring Living, this dedicated team is geared up to answer your...

Continue Reading
Intl Flavors & Fragrances Short Interest Insights and Trends

Updated Category News Views 141

Understanding Short Interest for Intl Flavors & Fragrances International Flavors & Fragrances Inc (NASDAQ: IFF) has been experiencing notable fluctuations in its short interest, a key metric for investors. Recently, the company reported a decline of 5.37% in its short percent of float since the last update. Currently, 5.42 million shares are sold short, which constitutes...

Continue Reading
Exploring the Growth of RFID Tags Market Towards 2032

Updated Category News Views 161

RFID Tags Market Size and Growth Projections The RFID tags market is on the rise, with projections indicating a market size of USD 29.05 billion by 2032. This growth stems from technological advancements and an increase in the adoption of RFID technology across different sectors. The market was valued at USD 12.42 billion in 2023, showcasing a compound annual growth rate...

Continue Reading
DataMesh Robotics Revolutionizes Industrial AI Training

Updated Category News Views 188

DataMesh Robotics Unveils a New Era in Industrial AI Training DataMesh, a prominent provider of digital twin technology and spatial intelligence solutions, has recently introduced DataMesh Robotics. This innovation is tailored to meet the needs of industrial and facility management scenarios, primarily through the use of embodied AI. The heart of this solution lies in the...

Continue Reading